The higher dependency of AML CD34+ cells on BCL-2 has led to therapies based on targeting BCL-2, which might spare normal haematopoietic stem cells (HSC) which were shown to depend more on MCL-1 for their survival [111,112,113]. This evidence concerns the gene BCL2 and acute myeloid leukemia.